Gadolinium-160 ,Gd-160

The Strategic Role of Gd-160 in Manufacturing Terbium-161 for Precision Cancer Treatment

Industry News

The Strategic Role of Gd-160 in Manufacturing Terbium-161 for Precision Cancer Treatment BY Tao, Published Dec 28, 2025   The landscape of targeted radionuclide therapy is undergoing a transformative shift. After more than two decades immersed in isotope research and production, Terbium-161 (Tb-161) represents something genuinely exceptional—a therapeutic radionuclide that may fundamentally enhance how we approach…

Gadolinium-160 ,Gd-160

Gadolinium-160 Target Material: A Game-Changer for Next-Generation Beta Therapy in Oncology

Industry News

Gadolinium-160 Target Material: A Game-Changer for Next-Generation Beta Therapy in Oncology BY Tao, Published Dec 28, 2025 Gadolinium-160 (Gd-160) is not a “therapy isotope” itself—it is a strategic stable target material that enables reliable reactor production of Terbium-161 (Tb-161), one of the most compelling next-generation radionuclides for targeted beta therapy and theranostics (therapy + imaging) in oncology. What makes this pathway special…

Gadolinium-160 ,Gd-160

Gadolinium-160: The Essential Precursor for Terbium-161 Production in Targeted Cancer Radiotherapy

Industry News

Gadolinium-160: The Essential Precursor for Terbium-161 Production in Targeted Cancer Radiotherapy BY Tao, Published Dec 28, 2025   Terbium-161 (Tb-161) is emerging as one of the most promising “next-step” therapeutic radionuclides for targeted radionuclide therapy (also called targeted radiotherapy or radioligand therapy) because it behaves chemically like the widely used Lutetium-177 (Lu-177), yet delivers additional ultra-short-range electron dose that…